Alembic Pharmaceuticals received USFDA final approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, equivalent to Zylet. The product earned CGT designation, granting 180 days of exclusivity. This marks Alembic’s 231st ANDA approval, strengthening its U.S. generics portfolio and boosting its position in ophthalmic therapies.
Alembic Pharmaceuticals Ltd has achieved a significant milestone with the final approval from the US Food & Drug Administration (USFDA) for its Loteprednol Etabonate and Tobramycin Ophthalmic Suspension (0.5%/0.3%). This product, available in 5 mL and 10 mL presentations, is therapeutically equivalent to Zylet Ophthalmic Suspension, used for treating steroid-responsive inflammatory ocular conditions with existing or potential bacterial infections.
Key highlights from the announcement:
-
Regulatory Win: Alembic received Competitive Generic Therapy (CGT) designation, granting 180 days of market exclusivity upon commercialization.
-
Product Scope: The ophthalmic suspension combines anti-inflammatory and antibacterial properties, addressing a critical therapeutic need in eye care.
-
Market Impact: With exclusivity, Alembic gains a competitive edge in the U.S. generics market, potentially boosting revenues.
-
Track Record: This approval adds to Alembic’s robust pipeline, bringing its cumulative USFDA tally to 231 ANDA approvals (211 final and 20 tentative).
-
Strategic Growth: The approval underscores Alembic’s focus on expanding its specialty portfolio and strengthening its presence in regulated markets.
This latest approval positions Alembic strongly in the ophthalmic generics space, reinforcing its reputation for innovation and regulatory compliance.
Sources: FilingReader, ScanX News, Investywise